Achaogen Announces Fourth Quarter and Full Year 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Achaogen Announces Fourth Quarter and Full Year 2014 Results

SOUTH SAN FRANCISCO, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO ), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter and year ended December 31, 2014.

During the fourth quarter, the Company remained focused on advancing the Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial for plazomicin, Achaogen's lead product for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). The Company has been exploring strategies to improve patient recruitment and remains in discussions with the US Food and Drug Administration (FDA) regarding potential modifications to the study design as well as additional clinical trials that could support and, possibly, facilitate regulatory filings for plazomicin. The Company currently expects to provide an update on its development plans for plazomicin by early in the second quarter of 2015.

"The past year has been important on multiple fronts, highlighted by our transition to being a public company, initiation of a Phase 3 trial to evaluate plazomicin, and participation in key legislative initiatives addressing the public health threat of antibiotic-resistant bacterial pathogens. As we head into 2015, I believe that the company is well positioned to become a worldwide leader in the antibiotic space," commented Dr. Kenneth Hillan, Chief Executive Officer of Achaogen.

Highlights for 2014

  • Completed $82.8 million initial public offering underwritten by Credit Suisse Securities (USA) LLC, Cowen and Company, LLC, William Blair & Company, LLC and Needham & Company, LLC.
     
  • Commenced patient enrollment into the Phase 3 CARE trial for plazomicin. This pathogen-specific trial is currently enrolling patients with a high risk of mortality and, if successful, will provide clinical evidence of the overall survival superiority of plazomicin versus colistin for life-threatening bloodstream infections and pneumonia due to CRE. Enrollment in the current Phase 3 clinical trial of plazomicin continues at a rate that has been slower than anticipated.
     
  • Progressed CARE trial site activation, with the majority of sites in the US and Europe now activated, and Latin America achieving on-line status in the first quarter of 2015.
     
  • Received Qualified Infectious Disease Product (QIDP) designation for plazomicin from the FDA. The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was part of the FDA Safety and Innovation Act (FDASIA) and provides certain incentives for the development of new antibiotics, including priority review and an additional five years of market exclusivity.
     
  • Dr. Kenneth Hillan, Chief Executive Officer of Achaogen, testified before the US House of Representatives Energy and Commerce Committee, Subcommittee on Health, providing testimony regarding federal initiatives to incentivize new antibiotic development, including the proposed ADAPT and DISARM Acts. The ADAPT Act (Antibiotic Development to Advance Patient Treatment) aims to establish a pathway for the prompt approval of antibacterial and antifungal drugs that are intended to treat serious or potentially fatal infections. The DISARM Act (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms) would reform reimbursement of qualifying antimicrobial products in the hospital setting to allow value-based pricing, thus providing a powerful incentive for manufacturers to develop new antibiotics.
     
  • Continued to leverage expertise and leadership in antibacterial research and development to advance discovery-stage programs, furthering the LpxC inhibitor and therapeutic antibody programs, which target MDR gram-negative bacteria including P. aeruginosa and A. baumannii .
     
  • Key appointments included John Smither and Dr. Chris Boerner to its Board of Directors, Dr. Ian Friedland becoming Chief Medical Officer, and Derek Bertocci joining as Chief Financial Officer.

Summary Financial Results for the Quarter and Year Ended December 31, 2014

Cash, cash equivalents and short-term investments totaled $63.7 million at December 31, 2014 compared to $72.0 million at September 30, 2014, decreasing as a result of operating losses and payment of a $4.0 million development milestone license fee which was accrued as expense in September 2014.

Revenues for the full year 2014 totaled $20.0 million, as compared to $18.5 million in 2013. Fourth quarter 2014 revenues were $4.3 million, compared to $6.2 million for the comparable quarter of 2013. Achaogen derived all of its revenue from funding provided under U.S. government contracts in connection with the development of product candidates. Revenue under government contracts increased due to increased spending on Achaogen's ongoing Phase 3 CARE trial of plazomicin.

Research and development (R&D) expenses for the years ended December 31, 2014 and 2013 were $30.1 million and $23.5 million, respectively. For the fourth quarter of 2014, R&D expenses were $6.6 million, compared to $6.8 million for the comparable quarter of 2013. Increased costs for 2014 were primarily attributable to increased activities on the ongoing Phase 3 trial of plazomicin, higher personnel-related expenses, and a $4.0 million development milestone license fee upon dosing the first patient in the Company's ongoing Phase 3 trial of plazomicin. This $4.0 million milestone fee was paid in October.

General and administrative (G&A) expenses for the years ended December 31, 2014 and 2013 were $9.6 million and $7.0 million, respectively. For the fourth quarter of 2014, G&A expenses were $2.5 million, compared to $1.6 million for the comparable quarter of 2013. Increased costs for 2014 and the quarter ended December 31, 2014 were primarily attributable to higher personnel-related costs including stock-based compensation expenses and increased costs associated with being a public company.

Net loss for the year ended December 31, 2014 was $20.2 million, compared to $13.1 million for the same period of 2013. Net loss in the fourth quarter of 2014 was $4.9 million, compared to a net loss of $2.5 million for the comparable quarter of 2013.

About Achaogen

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE. Through the Special Protocol Assessment procedure, the U.S. Food and Drug Administration has agreed that the design and planned analyses of Achaogen's Phase 3 CARE trial adequately address objectives in support of a New Drug Application.  Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Achaogen's expectations regarding the enrollment and success of its Phase 3 trial for plazomicin, Achaogen's ability to modify the current Phase 3 trial of plazomicin or to design and complete additional clinical trials of plazomicin that could support regulatory filings for plazomicin, Achaogen's ability to provide clinical evidence of the overall survival superiority of plazomicin versus colistin for life-threatening bloodstream infections and pneumonia due to CRE, Achaogen's ability to become a leading anti-infective company, and Achaogen's ability to discover, develop and commercialize novel antibacterials to treat MDR gram-negative infections. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; specific risks related to the Phase 3 trial of plazomicin, including the lack of a prior clinical trial in patients with CRE infections and challenges in enrolling an adequate number of patients with rare infections; the risk of failure to successfully validate, develop and obtain regulatory clearance or approval for the in vitro diagnostic (IVD) assay for plazomicin; the risks and uncertainties of the regulatory approval process; the risks and uncertainties of commercialization and gaining market acceptance; the risk that bacteria may evolve resistance to plazomicin; Achaogen's dependence on ARK Diagnostics, Inc. to develop and manufacture the IVD assay for plazomicin; risks and uncertainties as to Achaogen's ability to raise additional capital to support the development of plazomicin and its other programs; uncertainties regarding the availability of adequate third-party coverage and reimbursement for newly approved products; Achaogen's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; Achaogen's reliance on third-party contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof; Achaogen's dependence on its Chief Executive Officer; risks and uncertainties related to the acceptance of government funding for certain of Achaogen's programs, including the risk that the Biomedical Advanced Research and Development Authority could terminate Achaogen's contract for the funding of the plazomicin development program; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission on March 16, 2015. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

 
 
Achaogen, Inc.
Condensed Consolidated Statements of Operations
(in thousands except share and per share data)
(Unaudited)
         
  Three Months Ended Dec 31, Year Ended Dec 31,
  2014 2013 2014 2013
         
Contract revenue  $ 4,259  $ 6,192  $ 19,970  $ 18,512
Operating expenses:        
Research and development  6,632  6,799  30,110  23,484
General and administrative  2,508  1,574  9,646  6,992
Total operating expenses  9,140  8,373  39,756  30,476
         
Loss from operations  (4,881)  (2,181)  (19,786)  (11,964)
         
Interest expense  --  (227)  (397)  (1,331)
Other income (expense), net  27  (78)  7  183
         
Net loss  $ (4,854)  $ (2,486)  $ (20,176)  $ (13,112)
         
Basic and diluted net loss per common share  $ (0.27)  $ (6.33)  $ (1.42)  $ (33.83)
Weighted-average common shares outstanding used to        
calculate basic and diluted net loss per common share  17,785,923  392,844  14,210,098  387,547
 
 
Achaogen, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
     
  December 31, December 31,
  2014 2013
     
Assets    
Current assets:    
Cash and cash equivalents  $ 18,881  $ 10,738
Short-term investments  44,798  --
Contracts receivable  5,234  7,230
Prepaids and other current assets  520  1,873
     
Total current assets  69,433  19,841
Property and equipment, net  725  743
Restricted cash  127  127
Deposit and other assets  37  47
     
Total assets  $ 70,322  $ 20,758
     
Liabilities, convertible preferred stock, and stockholders' equity (deficit )    
Current liabilities:    
Accounts payable  $ 2,122  $ 2,923
Accrued liabilities  3,266  3,004
Notes payable, current portion  --  4,989
Other current liabilities  128  73
Total current liabilities  5,516  10,989
     
Deferred rent  193  125
Notes payable, noncurrent portion  --  1,698
Other long-term liabilities  --  244
Total liabilities  5,709  13,056
     
Convertible preferred stock  --  132,278
     
Stockholders' equity (deficit)  64,613  (124,576)
Total liabilities, convertible preferred stock, and stockholders' equity (deficit)  $ 70,322  $ 20,758

Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 105

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 148

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 91

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 58

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 144

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading

Top 5 Most Recently Viewed Articles

AI Data Risks and the Urgent Need for Enhanced Security Measures

Updated Category News Views 233

AI Data Security Threats Revealed by Varonis In a recent study conducted by Varonis, a prominent data security firm, alarming findings have surfaced regarding the vulnerabilities in organizations’ data systems. The report indicates that an overwhelming 99% of businesses have sensitive data that is exposed to artificial intelligence (AI) tools. This raises significant...

Continue Reading
Volt Lithium's Groundbreaking Daily Output Achieved with New Tech

Updated Category News Views 170

Volt Lithium Achieves Remarkable Milestone Volt Lithium Corp. is excited to announce that it has completed a 24-hour continuous run of its Generation 5 Field Unit, achieving an impressive throughput of 11,573 barrels per day. This significant milestone not only exceeds the initial target of 10,000 barrels per day but also demonstrates the company’s rapid advancements in...

Continue Reading
Investors Urged to Act Before PepGen Legal Deadline Approaches

Updated Category News Views 169

Urgent Reminder for PepGen Investors As the deadline approaches, it is vital for affected investors to take immediate action regarding their stakes in PepGen Inc. The renowned law firm, Bragar Eagel & Squire, P.C., is advocating for those who have incurred losses related to their investments in PepGen (PEPG). If you have purchased or otherwise acquired securities in...

Continue Reading
Gaumont's Voting Rights and Share Capital Information Revealed

Updated Category News Views 166

Gaumont’s Recent Disclosure on Voting Rights and Share Capital Gaumont, a well-known name in the film industry, recently shared important details about its voting rights and share capital. This information is crucial for current and prospective investors, providing transparency and clarity regarding the company’s governance structure. Key Details as per Article L....

Continue Reading
EAM-Mosca to Showcase Innovative Packaging Solutions at Expo

Updated Category News Views 170

EAM-Mosca to Showcase Innovative Packaging Solutions at SuperCorr Expo EAM-Mosca is excited to announce its participation in the upcoming SuperCorr Expo, where it will present its latest state-of-the-art strapping and wrapping solutions at Booth #2031. Attendees will have the opportunity to see firsthand how these solutions can improve efficiency and provide enhanced...

Continue Reading